Palatable pergolide paste for PPID: BEVA award for Rendle presentation on clinical research into new treatment option for "equine cushings disease"

Many ponies and horses suffer from pituitary pars intermedia dysfunction (PPID), known in the past as equine cushings disease.  Among the common clinical signs of the endocrine-related condition, seen commonly in older (but not exclusively older) animals are long, non-shedding coats and chronic laminitis. PPID can, in most cases, be successfully managed by the medication pergolide mesylate, which is currently only FDA-approved in a poorly palatable tablet. A recent presentation on an alternative form of the medication has been recognized with a prize from the British Equine Veterinary Association.

Research into what may one day be a significant advance in options for the treatment of horses with pituitary pars intermedia dysfunction (PPID), once known as equine cushings disease, has received an award in the United Kingdom.

Research overview: Preventing laminitis by studying insulin dynamics in older horses

Laminitis research comes in many forms. Recently, the emphasis has been on understanding the cause of the disease, and developing ways to prevent horses from ever knowing laminitic pain. The emphasis is on understanding how horse management and feeding can effect hormonal balances in older horses, and what recommendations might help horses live longer and healthier lives.